1 Additional Methods
Details on countries included
"DJI" "MAR" "KWT" "PAK" "IRN" "IRQ" "BHR" "QAT" "SYR" "TUN" "YEM" "LVA" "IRL" "CZE" "CYP" "GRC" "MNE" "MDA" "AUT" "FRA" "BLR" "DEU" "BIH" "NLD" "ARM" "HRV" "LUX" "SWE" "RUS" "GBR" "TJK" "GEO" "SVN" "NOR" "LTU" "PRT" "AZE" "ESP" "CHE" "POL" "TKM" "BEL" "TUR" "SVK" "BGR" "EST" "UKR" "FIN" "ALB" "MKD" "SRB" "DNK" "HUN" "ITA" "KGZ" "UZB" "ISR" "KAZ" "ROU" "IND" "THA" "PRK" "BTN" "NPL" "LKA" "BGD" "IDN" "MMR" "JPN" "FJI" "CHN" "NZL" "KOR" "MYS" "MAC" "KHM" "SGP" "AUS" "PHL" "PNG" "HKG" "MNG" "VNM"
MDR-TB incidence case burden in 2016
To calculate the number of MDR-TB incident cases in 2016 (for estimation of relation proportion of MDR-TB included), the average of the percentage of new and previously treated cases that was MDR-TB of those rifampicin resistant was calculated. This average was used to multiply the number of incident rifampicin resistant cases in each country. The levels in 2016 were used as this was the first year that estimates for all countries had been reported, either from survey or surveillance data or a modelled level.
Excluded high MDR-TB countries
Two of the 30 high MDR-TB burden countries [2] were missing from the 138: Angola and The Democratic Republic (DR) of the Congo. Both settings have had no drug resistance survey despite high levels of MDR-TB having been observed. In Angola, especially high levels are seen in retreatment cases (e.g. 71% [3] ) whilst in the DR Congo civil unrest has left the country with fragile health systems and a scarcity of data on MDR levels [4] . Despite being in the top TB and TB-HIV burden countries, we excluded both countries as there was no WHO DRS data.
Countries with only sub-national data
Seven countries (ISO3: "BRA" "CAF" "GIN" "IDN" "IND" "PNG" "PRK"), have only sub-national data. As these included three of the 30 high MDR settings (India, Indonesia and Papua New Guinea) it was decided that these could not be removed. Instead, where multiple sub-national surveys were taken on the same year a simple average was taken, and the overall percentage of new cases that was MDR from the sub-national surveys was used as an estimate for the whole country. This was also true for countries where multiple sub-national surveys were taken on single years from different sub-national regions (e.g. Oblasts for Russia).
WHO data 1.2.1 When does WHO DRS data exist?
The data provided by the WHO on the proportion of MDR in new and previously treated cases is mostly from the year 2000 onwards (Figure 1 ). Only one country (Algeria) has any data before 1990. The uncertainty in the WHO data is given for the data collected from surveys. For the data collected from surveillance a 95% Binomial Confidence interval was calculated (using the Wilson method) and used in the analysis.
1.3
Priors for parameters in model for trend 1.3 
.1 Appearance of MDR-TB
For each country a year in the past, t m , when MDR-TB appeared in a country was fitted. We are interested in MDR-LTBI in 2014. In 1970, it was first shown that including rifampicin (or pyrazinamide) alongside isoniazid, within the then "standard" streptomycin / isoniazid regimen substantially reduced subsequent relapse rate [5] . By 1981, in Britain, a combination of rifampicin and isoniazid was the recommended treatment [6] . DOTS (directly observed, short course therapy) was rolled out worldwide in 1995 [7] . A previous modelling study assumed transmissible MDR-M.tb strains arose 20-60 years before 2013 (1953 1993) [8] .
Hence, MDR is assumed to have appeared at detectable levels in a country somewhere between 1970 and 2000 (i.e. 1970 ¡ t m ¡ 2000). Assuming that the initial uptake of TB treatment was slow [9] , we assume a mean appearance in 1985, with a 95% confidence interval that it was between 1970 and 2000. Hence:
(1)
Equation for trend
Given this time, we then assumed that the proportion of new TB cases that were MDR (y) could increase in the form of a quadratic, where t is time.
We would like there to be no MDR-TB before t m . Hence we use the formulation:
This sets the proportion of new TB cases that were MDR to be zero at t m . In order for the trend to increase from time t m (when MDR first appeared) and then (potentially) reach the second zero we need the second solution of this equation to occur at t > t m > 0. If t m were zero, then y = 0 at t = b c . Otherwise, for the second zero to occur after t m requires:
What we would like to assume is that the second zero occurs at a time after 2014 as it is unlikely that any trend in the proportion of new TB cases that were MDR increases from zero at time t m , peaks and declines within the 1970-2014 period. If we make the assumption that c = rb tm we can calculate limits on the newly introduced scalar parameter r that prevent this occurring. If 
=> r < t m 2014 − t m
If we assume that the very earliest that t m can be is 1960, then in order for the second zero to occur after 2014, r must be less than 36 (substitute 1960 for t m into (8) ). Here r is the scalar parameter for calculation of c from b and t m . This assumes in general that from MDR-TB appearance to disappearance cannot take less than 55 years. For example, if r = 35, and MDR-TB appears in 1985 (t m = 1985), then the second zero is predicted to occur in 2041.
Assuming a uniform distribution for r is likely to lead to many declining trends in MDR-TB, when we know that few countries have evidence for this [10] . Instead a normal distribution with a mean of 5 and standard deviation of 15 gives a 95% range of values between -20 and 30.
Rate of increase
The rate of increase is dependent on both b and c. Previous modelling work has suggested that for those with a statistically significant linear trend in estimated per capita rates of MDR-TB among new notified TB cases the range of annual % change is -15% to 21% [10] . Negative trends arise when c < 0, by allowing r < 0.
We set the prior distribution for the parameter b to be lognormal (as we assumed, for the second zero to occur after t m , that it must be always positive) with a mean of −5.5 and standard deviation of 0.7. To reach this distribution, we assumed an upper limit of 1% for b. This prior was then tuned, within the multivariate analysis below, in order to give lower increases (around 0.1%) for the full range of WHO data trends to be captured.
Proposed priors
We can use this to generate priors for three parameters:
Here r has a truncated normal prior and is the dummy variable which allows us to calculate c from b and t m (the time when MDR first appears in a country):
These are summarised in Table 1 . Capped at 36 to prevent decrease of MDR to zero before 2014 Table 1 : Prior details for our model for trend: y = bt − ct 2 . Here y is the proportion of new TB cases with MDR, t is time, b is the coefficient of the rate of linear increase and c is the coefficient of the rate of quadratic change. The scalar term (r) is used to calculate the coefficient of the quadratic term c = rb/t.
Parameter Distribution Prior Notes

Effect of each parameter on trend
A uni-variate analysis of the output by parameter is shown in Figure 2 , with a two-way variation analysis shown in Figure 3a&b . Also shown here is the available data from the WHO DRS (for 138 countries, Figure 3c ). These prior outputs are only examples for one origin (t m ) time point for MDR (Figure 3a is 1975, Figure 3b is 1985), hence we would not expect perfect overlap of the output from the priors and the WHO DRS data. However, a comparison is useful as the overall levels can be seen to be similar. −17  −14  −11  −8  −5  −2  1  4  7  10  13  16  19  22  25  28  31  34 (c) r 
Model fitting details
We used 2 separate Markov Chain Monte Carlo runs of 20,000 iterations with the first 50% discarded as "burn-in" and the remainder thinned by a factor of 10. We took the samples as the last 200 from the first chain. 
Sensitivity analysis 3: trend analysis
We also considered more complex curves for some settings in which we deemed there to be sufficient information and trends in the data that suggested more complex dynamics in MDR-TB ARI. In particular, several settings had what could be deemed "peak and crash" dynamics: major changes in MDR-TB treatment practices might be expected to produce an asymmetric trend in ARI, with a peak followed by a (rapid) decline and then potentially continued growth but at a reduced rate.
Countries included in sensitivity analysis 3
To reduce the chance of overfitting we followed the below algorithm to perform the sensitivity analysis only in settings that contributed significantly to global MDR-TB burden in 2016 and had what we deemed to be "sufficient" data.
1.
Countries with sufficient data The first step was to determine which countries had sufficient data to which a more complex curve could be fitted. We set this to be at least five data points, which leaves 49 countries from the 138.
Peak before 2010
The second step was to remove those with no discernible "peak and crash" dynamics. To do this we set that a peak level in the data had to occur before 2010 (to allow for at least 5 years for the post peak trend). We calculated the moving average level (over 3 years) from the data to smooth out outliers. This left a subset of 23 countries (Figure 4 ).
3. Sufficient contribution to MDR levels Of these 23, only China and India are in the top 30 MDR burden countries. Indeed, these two countries are the only ones that contribute more than 0.1% of the total incident MDR-TB burden in 2016. Of our estimates of the number of people with MDR-LTBI in 2014, each of these 23 countries contributed less than 0.1% of the burden apart from China (30%), India (21%) and the USA (0.17%).
Following this algorithm we performed the more flexible model fitting for just these three countries: China, India and the USA.
Complex curve fitting in sensitivity analysis 3
We used the "smooth.spline" function in R to fit smoothed splines to the WHO data for the three final countries. This is a highly flexible model that we fit to the WHO data on the proportion of new TB cases that were MDR with an additional zero data point at 1970. As The 23 countries with sufficient data and potential "peak and crash" dynamics. The red line at 2010 was taken as the cut-off before which a peak should have occured to be included in this sensitivity analysis. The line is the 3 year moving average.
this function fits exactly to the data given, we took 200 samples of "data": for each time point with data, we sampled from a normal distribution with mean equal to the average data point and a standard deviation calculated assuming the upper and lower limits of the data represented a 95% confidence interval. These 200 samples then multiplied the ARI from the previous study to give DS-and MDR-ARI over time as in the main analysis.
As the number of data points varied for each country, we had to vary the internal smooth parameter for the spline function (lambda). For the USA, China and India we used lambda values of 5 × 10 −5 , 5 × 10 −5 and 1 × 10 −3 respectively. These values were chosen to minimise negative predictions and to prevent overfitting. 
Model construction
The model function (cohort ltbi mdr, built in R), requires two inputs: the ARI for DS-TB and MDR-TB over time and the population size in 2014. Two matrices are constructed ("now" & "last"), which track the following infections states, for each age group (row), for a certain year (column):
3. Current total infection: The total proportion infected with DS-TB in "now" matrix is the sum of the proportion previously infected in "last" 10. The proportion of reinfections is calculated for those with MDR-TB that get successfully re-infected with DS-TB (p rers = ari DS × αp r )
11. The proportion of reinfections that do not change the infecting strain (p ress and p rerr ) are calculated for estimating the levels of recent infection.
12. Set "last" matrix to be this "now" matrix and store 13. Repeat 2-12 for all years (1934 -2014) 14. Multiply the proportions in 2014 by the UN population size in each age group (1-100)
Initial conditions
The initial conditions are calculated assuming a constant ARI pre-1934 which is the ARI value in 1934 (ari 1934 ). There is assumed to be no MDR-TB pre-1960. The initial proportion infected with DS-TB in each age group i is
Key assumptions
The key assumptions that this cohort model makes are that
• LTBI is with the last strain to cause infection. This simplifies the analysis: we do not consider the impact of mixed infections nor the impact of re-infection on reactivation of previous or newly infecting strains.
• Annual risk of infection is homogeneous across all age groups.
• Infection with susceptible strains happens "first" in a year. This shouldn't affect results.
Metric for MDR-LTBI data coverage
Using the cohort model, we can track when infections with MDR-M.tb occurred and hence calculate how much MDR-LTBI was acquired in each 5 year time period in the past.
To do this, we took the prevalence of LTBI (DS or MDR) in each of 100 age groups in 2014. We then asked from which year was this LTBI acquired. For example, those aged 20 in 2014 were age 1 in 1995. By looking at the prevalence of LTBI in one year olds in 1995 and how this changed to two year olds in 1996, we can ask what proportion of the LTBI prevalence in 2014 was acquired at each time point. As the LTBI prevalence can decrease (especially for DS-TB), we calculated the sum of all the positive cumulative increases in prevalence of the lifetime of each age group and divided by their total to give percentage contributions for each year. This makes the assumption that any decrease in prevalence removes LTBI acquired equally across all previous years. Only the cumulative change is considered (i.e. the proportion that was due to assumed DS infection prior to 1934 is removed).
As the prevalence of LTBI varies by age, and the age groups are different sizes, these need to be taken into account when estimating when contributed most to LTBI burden in 2014. Hence, the population size in 2014 is used to convert the prevalence of LTBI at each age group into the actual numbers with LTBI in 2014. The proportions of the total population with LTBI in 2014 that was infected in each previous 5 yr time unit was then derived.
These proportions were multiplied by a 0 or 1 dependent on the availability of WHO data in that 5 yr time unit. This gives a metric which is 1 when all time periods that contribute to MDR-LTBI burden have supporting data.
Code
The code for the cohort model and calculations of trend, with some data and country level results, can be found at: https://github.com/gwenknight/MDR-LTBI-estimates 2 Additional Results
Top 10 countries by number with MDR-LTBI
The 10 countries with the higher number of people with MDR-LTBI is shown in Figure  5 . Note that although China and India dominate in terms of numbers, they have a low prevalence of MDR-LTBI. 
Model fits for each country
The 200 model fits for each country are given in Figure 6 . Here, both the linear and quadratic trends can be seen, for example in Bulgaria ("BGR") and Chile ("CHL"). Our assumptions about a not-too drastic rate of MDR increase means that we do not fit some of the higher, earlier data points (e.g. for Iran "IRN" and Morocco "MAR").
(a) Countries ALB -BTN 
Proportion infected by age
The proportion with DS-LTBI or MDR-LTBI is given in Figure 7 . 
Metric for MDR-LTBI data availability
Our metric for MDR-LTBI data availability is 1 when data is available in all 5-year time periods in which some MDR-LTBI in 2014 are acquired. A value of 0.5 suggests that 50% of the MDR-LTBI burden comes from time periods with data. Many countries have values of this metric above 0.5 ( Figure 8 ). However, the variation with trend is high ( Figure 9 ) and some countries have few data and so always low MDR-LTBI data coverage. For the top 30 countries ( Figure 10 ) most had values below 0.5. An example of the contributing 5-year time period levels for Botswana is given in Figure 11 .JPN  CHN  KOR  VNM  MAC  SGP  AUS  PHL  PNG  NZL  MYS  HKG   DNK  GBR  GEO  SWE  AUT  ITA  IDN  BTN  PRK  BGD  LKA  THA  NPL  MMR  IND  FJI  MNG  KHM   NOR  RUS  SVN  CYP  ALB  POL  ISR  IRL  ROU  TUR  KGZ  HUN  TKM  MNE  LVA  PRT  UZB  UKR   CZE  TJK  KAZ  ESP  NLD  SRB  FRA  CHE  MKD  SVK  FIN  GRC  AZE  MDA  ARM  LUX  HRV 
Sensitivity analysis 1
Reducing the protective effect of MDR-LTBI to reinfection results in output that is very similar to the main results (Table 2) . 
WHO
Estimated levels
The new results are shown in 
